Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc to host SRP-9001 Micro-dystrophin R&D Day Transcript

Oct 11, 2021 / 12:30PM GMT
Release Date Price: R$26.85
Operator

Good day, and welcome to the Sarepta Therapeutics conference call and webcast for the SRP-9001 Micro-dystrophin R&D day. (Operator Instructions) As a reminder, today's program is being recorded.

Now I'd like to turn the call over to Doug Ingram, President and CEO, for opening remarks.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you, Catherine, and good morning, everyone, and thank you for joining us today for what we are calling throughout as Micro-dystrophin Day.

First, remember, we will make a number of forward-looking statements today. Please refer to our various public filings for a list and discussion of the risks and uncertainties that come with making predictions about what may occur in the future. Now in a moment, Dr. Louise Rodino-Klapac will walk us through recent updates from our 3 ongoing studies, the Study 101, Study 102 and Study 103. And then we'll provide information on the protocol for our pivotal trial, Study 301, a study that we call EMBARK.

SRP-9001 represents the most

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot